Last updated: February 20, 2026
What are the case details and procedural history?
Bayer Schering Pharma AG filed a patent infringement lawsuit against Lupin Ltd in 2010 in the United States District Court for the District of Delaware. The complaint (filed December 10, 2010) alleges that Lupin's generic versions infringe U.S. Patent No. 6,773,720, licensed to Bayer, related to a proprietary oral contraceptive formulation.
- Patent involved: U.S. Patent No. 6,773,720, titled "Oral contraceptive formulations."
- Patent expiration date: July 2, 2023.
- Alleged infringement: Lupin's ANDA submission with a paragraph IV certification was made on October 4, 2010.
- Court's jurisdiction: Federal district court, district of Delaware.
Lupin responded by filing a paragraph IV certification under the Hatch-Waxman Act, challenging the patent's validity and non-infringement. Bayer initiated the high-stakes patent infringement litigation, triggering an automatic 30-month stay on FDA approval of Lupin's generic.
What are the key infringement and validity issues?
The core issues include:
- Infringement: Whether Lupin's proposed generic infringes Bayer’s patent through its formulation or manufacturing process.
- Invalidity: Whether the patent's claims are invalid under 35 U.S.C. §§ 102, 103, or 112. Lupin argued that the patent was obvious in light of prior art, notably prior formulations and references.
Lupin asserted that the patent claims were invalid due to obviousness over prior art references citing earlier oral contraceptive formulations. Bayer defended patent validity and infringement, emphasizing specialized formulation features that differentiate the patent.
What procedural actions occurred?
- Patent Office proceedings: Bayer obtained a patent that was challenged in external prior art references.
- Court proceedings: The parties filed motions for summary judgment, with Bayer seeking a judgment of infringement and validity.
- Expert testimonies: Both sides submitted expert reports, especially regarding obviousness and formulation specifics.
- Settlement: No published settlement has been confirmed publicly as of the last case update.
What significant rulings or orders have been issued?
As of the most recent filings, the case remained active with ongoing motion practice. No final judgment or dispositive ruling has been publicly reported. The critical procedural event was the court’s denial of Lupin's motion for summary judgment, ruling that there remain genuine issues of material fact regarding the patent's validity and infringement.
What are the potential implications of this case?
The litigation exemplifies the common Hatch-Waxman scenario where a generic manufacturer challenges patent validity while seeking market entry. An adverse ruling could delay Lupin’s entry, while a favorable outcome might lead to generic market approval before patent expiry.
- Patent strength: The patent's claims, if upheld, solidify Bayer’s exclusivity until July 2023.
- Market impact: A ruling invalidating the patent could permit Lupin to launch its generic earlier, affecting Bayer's market share and revenues.
What are the patent landscape considerations?
- The patent is part of a broader portfolio protecting oral contraceptives, a saturated segment with multiple overlapping patents.
- Validity challenges focus on obviousness, a frequent assertion against formulation patents when prior art exists.
- The case may influence patent strategies for pharmaceutical formulations, emphasizing unique features.
Final notes
No trial date has been set. The case remains a focus for generic-proof while Bayer defends its patent rights robustly. Outcomes hinge on the court's assessment of prior art and formulation distinctions.
Key Takeaways
- The case involves a patent infringement claim based on U.S. Patent No. 6,773,720, with allegations of infringement by Lupin's ANDA filing.
- Lupin challenged patent validity on obviousness grounds, leading to a significant patent dispute with potential market impact.
- The case's current procedural posture is active, with no final judgment yet issued.
- The outcome will influence the timing of generic entry and Bayer’s market exclusivity for the contraceptive product.
- Patent strength, validity defenses, and the court’s assessment of prior art will determine the case's resolution.
FAQs
1. What is the significance of a paragraph IV certification?
It indicates the generic manufacturer challenges the patent's validity or enforceability, triggering litigation and a patent-specific stay under the Hatch-Waxman Act.
2. How does obviousness impact patent validity?
Obviousness, under 35 U.S.C. § 103, considers whether the invention would have been obvious to a person skilled in the art at the time of invention. If so, the patent claims may be invalidated.
3. What happens if the court invalidates the patent?
Lupin could begin marketing its generic immediately or after the expiration of any remaining stay. Bayer would lose patent protection for the disputed formulation.
4. What are the typical timing considerations in Hatch-Waxman litigations?
A stay lasts for 30 months unless the court dismisses or rules sooner. Litigation often takes over two years to resolve, depending on case complexity.
5. What strategic steps do patent holders take in such disputes?
Patent holders often strengthen their patent portfolio, seek preliminary injunctions, or negotiate settlement terms early in litigation.
References
[1] U.S. District Court for the District of Delaware. Complaint: Bayer Schering Pharma AG v. Lupin Ltd, Case No. 2:10-cv-01166 (Dec. 10, 2010).
[2] U.S. Patent and Trademark Office. Patent No. 6,773,720.
[3] Hatch-Waxman Act, 21 U.S.C. § 355.
